PTC Therapeutics, Inc.
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS

Last updated:

Abstract:

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of .alpha.-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

25 Jan 2022

Issue date:

14 Jul 2022